Dr. Glenn is the President of Research and Development and is responsible for leading Novavax’ recombinant nanoparticle RSV F vaccine program. Dr. Glenn joined Novavax following the acquisition of the publicly-traded biotechnology company IOMAI by Intercell. As a founder of IOMAI, Dr. Glenn conducted pioneering work in vaccine antigen delivery via skin patch technology and succeeded in bringing several products from early concept into late-stage clinical development, evaluated in 35 clinical trials. Dr. Glenn, an associate editor of the journals Expert Review of Vaccines, and Human Vaccine, has published over 70 primary research and review articles, holds multiple U.S., European and other international patents and is a recognized innovator and leader in the field of vaccine delivery, discovery and translation to development. He trained in pediatrics at Madigan Army Medical Center, was board certified in Pediatrics, and completed a Medical Research Fellowship at the Walter Reed Army Institute of Research in Washington, D.C., where he worked in translational vaccine research from 1992 until 2000. Dr. Glenn received his Bachelor of Arts degree in Biology and Chemistry from Whitman College and his Doctor of Medicine degree from Oral Roberts University School of Medicine 

Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. Our vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins critical to disease pathogenesis.